Skip to content
It's time to build
Nav Opener
  • Portfolio
  • Team
  • Focus Areas
    • American Dynamism
    • Bio + Health
    • Cultural Leadership Fund
    • Consumer
    • Crypto
    • Enterprise
    • Fintech
    • Games
    • Growth
    • Talent x Opportunity
  • Content
    Topics
    • Fintech
    • Gaming & Social
    • Security & Privacy
    • Marketplaces
    • Enterprise & SaaS
    • Bio + Health
    • Creator Economy
    • Cryptocurrencies & Blockchains
    Type
    • Articles
    • Video
    • Podcasts
    • Newsletters
  • About
  • Jobs
Close

Becky Pferdehirt

Becky Pferdehirt

Becky Pferdehirt is a partner on the bio investing team. She focuses on early stage companies building technology platforms for therapeutic discovery and development.

Prior to joining Andreessen Horowitz, Becky worked at Amgen where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD Becky was a research scientist in Amgen R&D, focused on cell and gene therapy technology innovation.

Becky completed her postdoctoral education at Genentech studying cancer cell biology and proteomics. She holds a PhD in Molecular and Cellular Biology from UC Berkeley and a BS in Biology from MIT.

Latest Posts

Anatomy of a Biotech Business Development Deal

by Jorge Conde and Becky Pferdehirt
  • bio + health

New Year, New Fund, New Opportunities in Bio + Health

by Vineeta Agarwala, Jorge Conde, Justin Larkin, Vijay Pande, Becky Pferdehirt, Jay Rughani, Judy Savitskaya, Daisy Wolf, and Julie Yoo
  • bio + health
  • announcements
  • gene editing including CRISPR
  • healthcare
  • therapeutics
  • when science becomes engineering

From beckypferdehirt

Dan Nomura@DanNomura

Job openings at @VicinitasTx ! Be part of our team to develop next-generation drugs using our DUBTAC targeted protein stabilization platform! https://t.co/eHxHgp5C0s https://t.co/M9QikkP91y

Becky Pferdehirt@beckypferdehirt

Ideal cancer therapies are unlikely to be a single molecule and yet combination therapies are still rare today. IDRx is launching to address this crucial gap and bring transformational precision treatment to patients 💊💊💊 https://t.co/mVD7Kd2oln

Becky Pferdehirt@beckypferdehirt

I could not be more excited to share what we've been building at @VicinitasTx. Based on groundbreaking work from @DanNomura's group @UCBerkeley and @Novartis, Vicinitas is redefining small molecule druggability. https://t.co/8gBYHeFw7O

Software is eating the world
© 2022 Andreessen Horowitz
Software is eating the world
    • Twitter
    • Simplecast
  • Contact
  • Jobs
  • Briefings
  • Terms of Use & Privacy
  • Disclosures
  • Conduct
  • Who We Are